Influenza drug demand remains weak, Haleon (HLN.US) Q1 organic sales below expectations.

Intelligent Finance and Economics APP learned that due to the weak demand for over-the-counter cold and flu medications at the beginning of the year, Haleon (HLN.US) first-quarter performance was below expectations. The company, which produces Panadol and Advil pain relievers, stated on Wednesday that organic sales in the first quarter increased by 2.2%, lower than analysts' expectations of 2.4%. Revenue was 2.857 billion pounds, a year-on-year increase of 0.1%.